

# Richard W Tsang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5978596/publications.pdf>

Version: 2024-02-01

133  
papers

7,858  
citations

44069

48  
h-index

51608

86  
g-index

135  
all docs

135  
docs citations

135  
times ranked

6475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. <i>American Journal of Hematology</i> , 2022, 97, 583-591.	4.1	7
2	Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000–2015). <i>Radiotherapy and Oncology</i> , 2022, 173, 179-187.	0.6	7
3	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. <i>Leukemia</i> , 2021, 35, 130-142.	7.2	70
4	External Beam Radiotherapy for Thyroid Malignancy. , 2021, , 452-460.e2.		0
5	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1064-1081.	0.8	26
6	Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. <i>European Journal of Cancer</i> , 2021, 152, 129-138.	2.8	6
7	Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. <i>Frontiers in Endocrinology</i> , 2021, 12, 795184.	3.5	11
8	Radiotherapy in mantle cell lymphoma: A literature review. <i>Hematological Oncology</i> , 2020, 38, 223-228.	1.7	4
9	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	5.2	3
10	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. <i>Blood Advances</i> , 2020, 4, 2064-2072.	5.2	6
11	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 398-400.	0.8	5
12	Whole Brain Radiation Is Still the Standard in the Salvage Situation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 403.	0.8	0
13	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. <i>Annals of Surgical Oncology</i> , 2019, 26, 2533-2539.	1.5	18
14	A pilot study examining Toronto-area family physician perspectives on thyroid neoplasm evaluation. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2019, 48, 24.	1.9	2
15	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 347-351.	2.4	1
16	A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1662-1673.	4.5	53
17	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 794-808.	0.8	128
18	Symptom burden in adults with thyroid cancer. <i>Psycho-Oncology</i> , 2018, 27, 2517-2519.	2.3	5

#	ARTICLE	IF	CITATIONS
19	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2607-2614.	1.3	16
20	Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1116-1123.	0.8	93
21	Patterns of regional recurrence in papillary thyroid cancer patients with lateral neck metastases undergoing neck dissection. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 43.	1.9	7
22	Plasmacytoma and Multiple Myeloma. , 2017, , 85-96.		0
23	Concerns of low-risk thyroid cancer survivors. <i>Acta Oncologica</i> , 2016, 55, 1252-1253.	1.8	8
24	Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma. , 2016, , 671-708.		1
25	Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1454-1459.	0.8	21
26	Thyroid cancer survivors' perceptions of survivorship care follow-up options: a cross-sectional, mixed-methods survey. <i>Supportive Care in Cancer</i> , 2016, 24, 2007-2015.	2.2	22
27	Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. <i>Thyroid</i> , 2016, 26, 474-475.	4.5	17
28	Non-Hodgkin's Lymphoma. , 2016, , 1524-1546.e7.		2
29	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. <i>Blood</i> , 2016, 128, 4645-4645.	1.4	0
30	Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2016, 128, 3005-3005.	1.4	1
31	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 1659-1664.	1.3	24
32	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 144-152.	0.8	18
33	A single institution experience of extranodal natural killer/T cell lymphoma of nasal type. <i>Leukemia and Lymphoma</i> , 2015, 56, 80-84.	1.3	5
34	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 11-31.	0.8	303
35	Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults. <i>British Journal of Haematology</i> , 2015, 170, 384-390.	2.5	7
36	Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 48.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial. <i>Cancer</i> , 2015, 121, 3717-3726.	4.1	14
38	Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. <i>Practical Radiation Oncology</i> , 2014, 4, 174-180.	2.1	34
39	Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. <i>Head and Neck</i> , 2013, 35, 35-39.	2.0	49
40	Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. <i>British Journal of Haematology</i> , 2013, 162, 483-488.	2.5	89
41	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	1.3	14
42	Patients' experiences following local-regional recurrence of thyroid cancer: A qualitative study. <i>Journal of Surgical Oncology</i> , 2013, 108, 47-51.	1.7	34
43	Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. <i>Leukemia and Lymphoma</i> , 2013, 54, 261-267.	1.3	35
44	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. <i>Thyroid</i> , 2013, 23, 246-247.	4.5	9
45	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2906-2911.	1.6	40
46	Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. <i>Leukemia and Lymphoma</i> , 2012, 53, 836-841.	1.3	34
47	Role of Salvage Radiation Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e329-e335.	0.8	35
48	Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. <i>Haematologica</i> , 2012, 97, 751-757.	3.5	23
49	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
50	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	1.3	23
51	Palliation by Low-Dose Local Radiation Therapy for Indolent Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e781-e786.	0.8	46
52	Localized Orbital Mucosa-Associated Lymphoma Tissue Lymphoma Managed With Primary Radiation Therapy: Efficacy and Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e659-e666.	0.8	94
53	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	1.8	28
54	A usability study of a computerized decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment. <i>Patient Education and Counseling</i> , 2011, 84, e24-e27.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma. , 2011, , 31-44.		0
56	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica, 2010, 95, 1496-1502.	3.5	16
57	A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood, 2010, 116, 2237-2240.	1.4	63
58	Hodgkin Lymphoma Across the Age Spectrum: Epidemiology, Therapy, and Late Effects. Seminars in Radiation Oncology, 2010, 20, 30-44.	2.2	86
59	Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer, 2010, 116, 3815-3824.	4.1	172
60	Quantification of Local Tumor Response to Fractionated Radiation Therapy for Non-Hodgkin Lymphoma Using Weekly 18F-FDG PET/CT Imaging. International Journal of Radiation Oncology Biology Physics, 2010, 76, 850-858.	0.8	8
61	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial. Trials, 2010, 11, 81.	1.6	15
62	Differentiated Thyroid Cancer with Extrathyroidal Extension: Prognosis and the Role of External Beam Radiotherapy. Journal of Thyroid Research, 2010, 2010, 1-7.	1.3	30
63	Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review. Thyroid, 2010, 20, 1129-1138.	4.5	71
64	Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicities. Hematological Oncology, 2009, 27, 115-122.	1.7	4
65	Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 380-386.	1.3	27
66	Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. Thyroid, 2009, 19, 451-457.	4.5	296
67	The Impact of Thyroid Cancer and Post-Surgical Radioactive Iodine Treatment on the Lives of Thyroid Cancer Survivors: A Qualitative Study. PLoS ONE, 2009, 4, e4191.	2.5	61
68	Head and Neck Sarcomas and Lymphomas. Medical Radiology, 2009, , 103-115.	0.1	1
69	Solitary extramedullary plasmacytoma of the head and neck—Long-term outcome analysis of 68 cases. Head and Neck, 2008, 30, 1012-1019.	2.0	119
70	A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clinical Endocrinology, 2008, 68, 610-617.	2.4	69
71	A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clinical Endocrinology, 2008, 69, 479-490.	2.4	143
72	Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 775-782.	2.0	22

#	ARTICLE	IF	CITATIONS
73	An Updated Systematic Review and Commentary Examining the Effectiveness of Radioactive Iodine Remnant Ablation in Well-Differentiated Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 457-480.	3.2	230
74	External Beam Radiation Therapy for Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 497-509.	3.2	46
75	Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 1486-1493.	1.3	144
76	Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1329-1336.	1.3	88
77	CNS Hodgkin lymphoma. <i>Blood</i> , 2008, 112, 1658-1661.	1.4	76
78	Basis for Physician Recommendations for Adjuvant Radioiodine Therapy in Early-Stage Thyroid Carcinoma: Principal Findings of the Canadian-American Thyroid Cancer Survey. <i>Endocrine Practice</i> , 2008, 14, 175-184.	2.1	19
79	Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2007, 17, 1277-1288.	4.5	132
80	Regional Differences in Opinions on Adjuvant Radioactive Iodine Treatment of Thyroid Carcinoma within Canada and the United States. <i>Thyroid</i> , 2007, 17, 1235-1242.	4.5	17
81	Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. <i>Hematological Oncology</i> , 2007, 25, 11-15.	1.7	134
82	Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. <i>Cancer</i> , 2007, 110, 1451-1456.	4.1	246
83	Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. <i>Cancer</i> , 2007, 110, 2576-2586.	4.1	131
84	A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. <i>Radiation Oncology</i> , 2007, 2, 13.	2.7	128
85	Low-Grade Non-Hodgkin Lymphomas. <i>Seminars in Radiation Oncology</i> , 2007, 17, 198-205.	2.2	30
86	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3432-3432.	1.4	0
87	Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 210-217.	0.8	225
88	Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1183-1187.	0.8	28
89	Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 223-228.	0.8	65
90	Hodgkin's Lymphoma. <i>Current Problems in Cancer</i> , 2006, 30, 107-158.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. <i>BMC Cancer</i> , 2006, 6, 118.	2.6	164
92	Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. <i>Cancer</i> , 2006, 106, 353-360.	4.1	93
93	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. <i>Cancer</i> , 2006, 107, 1786-1792.	4.1	105
94	External Radiation Therapy of Medullary Cancer. , 2006, , 605-607.		1
95	External Radiation Therapy of Papillary Cancer. , 2006, , 485-489.		0
96	Advances in Radiation Therapy. , 2006, , 653-655.		0
97	External Radiation Therapy of Follicular Carcinoma. , 2006, , 545-548.		0
98	External Radiation Therapy of Anaplastic Thyroid Cancer. , 2006, , 641-642.		0
99	Radiation therapy for Bowen's disease of the skin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 505-510.	0.8	39
100	Radiation therapy for localized low-grade non-Hodgkin's lymphomas. <i>Hematological Oncology</i> , 2005, 23, 10-17.	1.7	73
101	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 2233-2239.	1.6	188
102	Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 764-772.	2.0	67
103	Impact of chest wall and lung invasion on outcome of stage II Hodgkin's lymphoma after combined modality therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1374-1381.	0.8	23
104	Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2003, 21, 4157-4164.	1.6	370
105	Role of radiation therapy in localised non-Hodgkin's lymphomas. <i>European Journal of Cancer</i> , Supplement, 2003, 1, 41-49.	2.2	0
106	Malignant Teratoma of the Thyroid: Aggressive Chemoradiation Therapy is Required After Surgery. <i>Thyroid</i> , 2003, 13, 401-404.	4.5	30
107	Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy. <i>Clinical Cancer Research</i> , 2003, 9, 4387-95.	7.0	9
108	Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 643-651.	0.8	29

#	ARTICLE	IF	CITATIONS
109	Radiotherapy management for squamous cell carcinoma of the nasal skin: the Princess Margaret Hospital experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 973-979.	0.8	59
110	Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue of the Lacrimal Gland. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 67-70.	1.3	25
111	Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 113-120.	0.8	253
112	Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 202-208.	2.5	79
113	Stage I and II malt lymphoma: results of treatment with radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1258-1264.	0.8	167
114	Results of radiotherapy for epithelial skin cancer of the pinna: the princess margaret hospital experience, 1982-1993. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 451-459.	0.8	119
115	Interrelationship of proliferation and hypoxia in carcinoma of the cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 95-99.	0.8	18
116	Mucosa-associated lymphoid tissue lymphomas. <i>Current Oncology Reports</i> , 2000, 2, 192-198.	4.0	10
117	Proliferation parameters in epidermoid carcinomas of the anal canal. <i>Radiotherapy and Oncology</i> , 2000, 56, 349-353.	0.6	18
118	External-beam radiation therapy in the treatment of differentiated thyroid cancer. , 1999, 16, 42-49.		88
119	Tumour proliferation and apoptosis in human uterine cervix carcinoma II: correlations with clinical outcome. <i>Radiotherapy and Oncology</i> , 1999, 50, 93-101.	0.6	42
120	Tumor proliferation and apoptosis in human uterine cervix carcinoma I: correlations between variables. <i>Radiotherapy and Oncology</i> , 1999, 50, 85-92.	0.6	23
121	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. <i>Cancer</i> , 1998, 82, 375-388.	4.1	351
122	Parathyroid carcinoma—the princess margaret hospital experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 569-572.	0.8	99
123	Prescribing <sup>131</sup> Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. <i>Radiotherapy and Oncology</i> , 1998, 47, 325-330.	0.6	38
124	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. <i>Cancer</i> , 1998, 82, 375-388.	4.1	11
125	A comparison of different staging systems predictability of patient outcome. <i>Cancer</i> , 1997, 79, 2414-2423.	4.1	237
126	A comparison of different staging systems predictability of patient outcome. <i>Cancer</i> , 1997, 79, 2414-2423.	4.1	29



#	ARTICLE	IF	CITATIONS
127	EXTERNAL RADIATION THERAPY IN THE TREATMENT OF THYROID MALIGNANCY. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996, 25, 141-157.	3.2	50
128	The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy-sensitive Relapsed and Primary Refractory Non-Hodgkin's Lymphoma: Identification of Major Prognostic Groups. <i>British Journal of Haematology</i> , 1996, 92, 880-889.	2.5	73
129	Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: Correlation between two laboratories and preliminary clinical results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 1319-1329.	0.8	63
130	Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity. <i>Biochemical Pharmacology</i> , 1995, 50, 55-60.	4.4	0
131	Lentigo Maligna of the Head and Neck. <i>Archives of Dermatology</i> , 1994, 130, 1008.	1.4	85
132	Radiation therapy for pituitary adenoma: Treatment outcome and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 557-565.	0.8	203
133	Non-hodgkin's lymphoma of the thyroid gland: Prognostic factors and treatment outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 599-604.	0.8	53